Steven Hyman, M.D.

Steven Hyman, M.D.

Harvard Department of Stem Cell and Regenerative Biology
The Broad Institute
Steven E Hyman, HSCI

Steven Hyman directs the Stanley Center for Psychiatric Research, and is interested in exploiting the emerging genetics of neuropsychiatric disorders to develop models that will facilitate the discovery of much-needed new therapeutics.

From 1996 to 2001, Hyman served as Director of the US National Institute of Mental Health (NIMH), the component of the NIH charged with generating the knowledge needed to understand and treat mental illness. At NIMH he emphasized investment in basic neuroscience and in the tools needed to analyze genetically complex disorders such as autism, schizophrenia, and bipolar disorder. As Provost of Harvard University, he served as Harvard’s chief academic officer, but had a special focus on the development of collaborative scientific initiatives that span multiple disciplines, that crossed the boundaries of Harvard’s schools and affiliated hospitals, and that extended to neighboring universities. 

Biosketch

Steven E. Hyman is a Harvard University Distinguished Service Professor of Stem Cell and Regenerative Biology and a Core Institute Member of the Broad Institute of Harvard and MIT, where he directs the Stanley Center for Psychiatric Research. The Stanley Center engages in large-scale, globally conducted studies of neuropsychiatric genetics, stem cell biology, neurobiology, and technology development in support of translational efforts focused on reducing the global burden of psychiatric disorders.

Hyman also serves as chair of the board of Charles A. Dana Foundation, which supports research and education in neuroscience. In addition, he is a Director of the Charles H. Revson Foundation, of the Wyss Center for Bio and Neuroengineering (Geneva, Switzerland) and of the nonprofit scientific publisher Annual Reviews Inc. In the private sector, he is a Director of Voyager Therapeutics and Q-State Biosciences and serves on the scientific advisory boards of Janssen Pharmaceuticals, BlackThorn Therapeutics, and F-Prime Capital.

From 2001 to 2011 Hyman served as Provost of Harvard University, the university’s chief academic officer. From 1996 to 2001, he served as Director of the U.S. National Institute of Mental Health (NIMH), where he emphasized investment in neuroscience and emerging genetic technologies. He also initiated a series of large practical clinical trials to inform practice.

Hyman has served as President of the Society for Neuroscience (2015), President of the American College of Neuropsychopharmacology (2018), founding President of the International Neuroethics Society (2008-2013), and Editor of the Annual Review of Neuroscience (2002-2016). He is a fellow of the American Academy of Arts and Sciences, a fellow of the American Association for the Advancement of Science, and a member of the National Academy of Medicine, where he served on the governing Council (2012-2018) and which he represented on the Governing Board of the National Research Council, the operating arm of the US National Academies of Sciences, Engineering, and Medicine (2016-2019). From 2012-2018 Hyman chaired the Forum on Neuroscience and Nervous System Disorders of the US National Academies, which brings together industry, government, foundations, patient groups, and academia. In 2016, he was awarded the Rhoda and Bernard Sarnat International Prize in Mental Health by the National Academy of Medicine.

Hyman received his B.A., summa cum laude, from Yale College, an M.A. from the University of Cambridge, which he attended as a Mellon fellow studying History and Philosophy of Science, and an M.D., cum laude, from Harvard Medical School.

Contact Information

Research Interest(s)

Year

Clinician-Scientist